RAC1 Inhibition Targets Amyloid Precursor Protein Processing by γ-Secretase and Decreases Aβ Production in Vitro and in Vivo
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
beta-Amyloid peptides (Abeta) that form the senile plaques of Alzheimer disease consist mainly of 40- and 42-amino acid (Abeta 40 and Abeta 42) peptides generated from the cleavage of the amyloid precursor protein (APP). Generation of Abeta involves beta-secretase and gamma-secretase activities and is regulated by membrane trafficking of the proteins involved in Abeta production. Here we describe a new small molecule, EHT 1864, which blocks the Rac1 signaling pathways. In vitro, EHT 1864 blocks Abeta 40 and Abeta 42 production but does not impact sAPPalpha levels and does not inhibit beta-secretase. Rather, EHT 1864 modulates APP processing at the level of gamma-secretase to prevent Abeta 40 and Abeta 42 generation. This effect does not result from a direct inhibition of the gamma-secretase activity and is specific for APP cleavage, since EHT 1864 does not affect Notch cleavage. In vivo, EHT 1864 significantly reduces Abeta 40 and Abeta 42 levels in guinea pig brains at a threshold that is compatible with delaying plaque accumulation and/or clearing the existing plaque in brain. EHT 1864 is the first derivative of a new chemical series that consists of candidates for inhibiting Abeta formation in the brain of AD patients. Our findings represent the first pharmacological validation of Rac1 signaling as a target for developing novel therapies for Alzheimer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091
Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1
Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., et al. (2000) · Nature · doi:10.1038/35015085 · Cited by 866
Association of γ-Secretase with Lipid Rafts in Post-Golgi and Endosome Membranes
Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., Wong, P. C., Xu, H., & Thinakaran, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407986200 · Cited by 413
Liao, Y.-F., Wang, B.-J., Cheng, H.-T., Kuo, L.-H., & Wolfe, M. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402034200 · Cited by 389
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352
Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß 42 by Inhibiting Rho
Zhou, Y., Su, Y., Li, B., Liu, F., Ryder, J. W., Wu, X., Gonzalez-DeWhitt, P. A., Gelfanova, V., Hale, J. E., May, P. C., et al. (2003) · Science · doi:10.1126/science.1090154 · Cited by 316
Cited by
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 882
PI3K signaling in cancer: beyond AKT
Lien, E. C., Dibble, C. C., & Toker, A. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.02.007 · Cited by 451
Shutes, A., Onesto, C., Picard, V., Leblond, B., Schweighoffer, F., & Der, C. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703571200 · Cited by 336
Self-citationThe role of amyloid β peptide 42 in Alzheimer's disease
Findeis, M. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.006 · Cited by 324
Cuadrado, A., Martín-Moldes, Z., Ye, J., & Lastres-Becker, I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.540633 · Cited by 320
Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis
Wood, W. G., Li, L., Müller, W. E., & Eckert, G. P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12637 · Cited by 194
Statins Reduce Amyloid-β Production through Inhibition of Protein Isoprenylation
Ostrowski, S. M., Wilkinson, B. L., Golde, T. E., & Landreth, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702640200 · Cited by 180
Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms
Marei, H., & Malliri, A. (2017) · Small GTPases · doi:10.1080/21541248.2016.1211398 · Cited by 168
Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases
(2008) · Methods in Enzymology · doi:10.1016/s0076-6879(07)00409-0 · Cited by 126
“Previous studies suggested that EHT 1864 is a Rac-specific inhibitor that can inhibit association of Rac with its effector Pak, as well as a variety of downstream Rac signaling pathways (Desire et al., 2005) (see Fig.”
BackgroundSelf-citationCholesterol and statins in Alzheimer’s disease: current controversies.
Fonseca, A. C. R. G., Resende, R., Oliveira, C. R., & Pereira, C. M. F. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.013 · Cited by 93
Modulation of actin dynamics by Rac1 to target cognitive function
Tejada‐Simon, M. V. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13100 · Cited by 76
“Also, and as previously reported for NSC23766, inhibition of Rac1 with EHT1864 both, in vitro and in vivo, results in the decrease of Abeta production (Desire et al. 2005), pointing to Rac1 inhibition as a possible therapy also for Alzheimer’s disease.”
BackgroundInfluentialMatrix stiffness modulates tip cell formation through the p-PXN-Rac1-YAP signaling axis
Guo, Y., Mei, F., Huang, Y., Ma, S., Wei, Y., Zhang, X., Xu, M., He, Y., Heng, B. C., Chen, L., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.033 · Cited by 74
Walliser, C., Hermkes, E., Schade, A., Wiese, S., Deinzer, J., Zapatka, M., Désiré, L., Mertens, D., Stilgenbauer, S., & Gierschik, P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.746842 · Cited by 51
Self-citationPharmacological Modulators of Small GTPases of Rho Family in Neurodegenerative Diseases
Guiler, W., Koehler, A., Boykin, C., & Lu, Q. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661612 · Cited by 51
Rac1 changes the substrate specificity of γ-secretase between amyloid precursor protein and Notch1
Boo, J. H., Sohn, J. H., Kim, J. E., Song, H., & Mook-Jung, I. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.153 · Cited by 32
Metadata
- Authors
- Désiré, L., Bourdin, J., Loiseau, N., Peillon, H., Picard, V., De Oliveira, C., Bachelot, F., Leblond, B., Taverne, T., Beausoleil, E., Lacombe, S., Drouin, D., & Schweighoffer, F.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-11
- Volume
- 280
- Issue
- 45
- Pages
- 37516-37525
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2101176536
- Cited by
- 135
- References
- 9
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.